Business
Sotera Health Reports Second-Quarter and First-Half 2021 Results; Increases 2021 Outlook
Q2 2021 net revenues of $252 million increased approximately 18%, compared to Q2 2020Q2 2021 net income of $43 million or $0.15 per diluted share, compared to
About this update from Sotera Health Company
[{"type":"text","content":"Q2 2021 net revenues of $252 million increased approximately 18%, compared to Q2 2020Q2 2021 net income of $43 million or $0.15 per diluted share, compared to net income of $7 million or $0.03 per diluted share in Q2 2020Q2 2021 Adjusted EBITDA of $135 million increased approximately 18%, compared to Q2 2020Q2 2021 Adjusted EPS of $0.26 improved $0.12 compared to Q2 2020 Adjusted EPS of $0.14June 30, 2021 total debt of $1.9 billion and net debt of $1.7 billion; net leverage ratio improved to 3.8xIncreasing full-year 2021 revenue growth outlook from 9%-12% to 12%-15% and increasing full-year 2021 Adjusted EBITDA growth outlook from 11%-16% to 13%-17%Full redemption of $100M Senior Secured First-Lien Notes due 2026 scheduled for Q3 2021 CLEVELAND, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the second quarter and first half of 2021. Second-quarter 2021 net revenues increased 18.2% to $252 million, compared with $213 million in the same period a year ago. Second-quarter 2021 net income attributable to Sotera Health (“net income”) was $43 million, or $0.15 per diluted share, compared with net income of $7 million, or $0.03 per diluted share in the second quarter of 2020. Adjusted EBITDA for the second-quarter 2021 increased 17.6% over the second quarter of 2020 to $135 million. Second-quarter 2021 adjusted earnings per diluted share (“Adjusted EPS”) was $0.26, compared to $0.14 in the second quarter of 2020, an increase of $0.12 per diluted share. Please refer to the section “Non-GAAP Financial Measures” provided later in this release. For the first six months of 2021, net revenues increased 15.6% to $464 million, compared to $401 million for the same period in 2020. Net income was $53 million, or $0.19 per diluted share for the first half of 2021, compared with net income of $5 million, or $0.02 per diluted share, for the same period last year. First half of 2021 Adjusted EBITDA increased 16.3% to $240 million and Adjusted EPS grew by $0.20 to $0.44 compared to the first half of 2020. Please refer to the section “Non-GAAP Financial Measures” provided later in this release. “Today, we are rep...